AZNAstraZenecaRunning, no new patients
BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
Non-Muscle- Invasive Bladder Cancer
10Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +10
Main results were due Jun 2025, none posted yet
Counts until it's fixed
Worry score10
Score over time
- Stage
- Phase 3
- Patients
- 100 (final count)
- Started
- Aug 11, 2023
- Main results expected
- Jun 16, 2025
- Fully finished
- Mar 31, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Grade 3 or 4 Possibly related adverse events (PRAEs)
Measured over: From the date of the first dose of study treatment (Day 1) until 6 months after the initiation of study treatment
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- results_overdue: base 10, now 10, since 2025-06-16, no fading
Raw record changes
- none yet
Trial ID NCT05943106 · record last updated 2026-08-13 · checked 2026-11-09 15:47 UTC